Tim-3促进树突状细胞铁死亡并损害脂肪性肝炎相关肝细胞癌的抗肿瘤免疫
该研究探讨MASLD-HCC中脂质微环境驱动免疫抑制的机制,发现高脂饮食诱导树突状细胞(DC)耗竭和CD8+ T细胞功能障碍,DC特异性Tim-3高表达与不良预后相关。Tim-3通过脂质过氧化和铁死亡导致DC耗竭,抑制Tim-3可恢复DC存活和CD8+ T细胞活化并抑制肿瘤生长,且与抗PD-1或仑伐替尼协同。
要点
- MASLD-HCC中脂质微环境通过Tim-3依赖的脂质过氧化诱导DC铁死亡。
- DC特异性Tim-3高表达与脂肪性肝炎相关HCC患者不良预后相关。
- Tim-3阻断与抗PD-1或仑伐替尼联用可协同控制肿瘤。
核心结论
- Tim-3是代谢性肝癌中DC铁死亡的关键调节因子。
- 联合Tim-3阻断与标准疗法可恢复MASLD-HCC的免疫监视。
研究设计与样本
- 研究分析HCC组织中DC-CD8+ T细胞相互作用,采用多重免疫荧光染色。
- 机制研究使用高脂饮食诱导的MASLD-HCC小鼠模型,进行Tim-3基因或药理抑制及DC清除或过继转移。
- 通过流式细胞术、转录组学和功能实验评估脂质过氧化、铁死亡和免疫相互作用。
- 在临床前模型中评估Tim-3阻断单用或联合抗PD-1或仑伐替尼的疗效。
主要发现
- 高脂饮食重塑肝脏肿瘤免疫微环境,诱导DC耗竭和CD8+ T细胞功能障碍,促进肿瘤进展。
- 人脂肪性肝炎相关HCC中DC浸润及DC-CD8+ T细胞相互作用明显受损,DC特异性Tim-3高表达与不良预后相关。
- 脂质丰富的微环境通过Tim-3依赖的脂质过氧化和铁死亡诱导DC耗竭。
- 遗传或药理抑制DC中Tim-3可减轻脂质过氧化,恢复DC存活和CD8+ T细胞活化,抑制肿瘤生长。
- Tim-3阻断与抗PD-1及仑伐替尼均有效协同,实现持续肿瘤控制。
临床怎么用
- 靶向DC中Tim-3阻断可能成为治疗脂肪性肝炎相关HCC的潜在策略。
- 对抗PD-1耐药的MASLD相关HCC患者,联合Tim-3阻断可能恢复免疫治疗敏感性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of hepatocellular carcinoma (HCC) and confers resistance to immunotherapy. However, the underlying mechanisms remain unclear. We aimed to elucidate how the lipid-rich microenvironment of MASLD-HCC drives immune suppression and to identify actionable targets. METHODS: Dendritic cell (DC)-CD8+ T cell interactions in HCC tissues were analyzed by multiplexed immunofluorescence staining. Mechanistic studies employed high-fat diet (HFD)-induced MASLD-HCC mouse models, genetic or pharmacological inhibition of Tim-3, and DC depletion or adoptive transfer. Lipid peroxidation, ferroptosis, and immune interactions were assessed using flow cytometry, transcriptomics, and functional assays. The therapeutic efficacy of Tim-3 blockade, alone or combined with anti-PD-1 therapy or lenvatinib, was evaluated in preclinical models. RESULTS: HFD reshaped the hepatic tumor immune microenvironment by inducing DC depletion and CD8+ T cell dysfunction, facilitating liver tumor progression. In human steatohepatitis-related HCC, DC infiltration and DC-CD8+ T cell interactions were markedly impaired, and high DC-specific Tim-3 expression correlated with poor prognosis. Mechanistically, the lipid-rich microenvironment induced DC depletion via Tim-3-dependent lipid peroxidation and ferroptosis. Genetic or pharmacological inhibition of Tim-3 in DCs attenuated lipid peroxidation, restored DC survival and CD8+ T cell activation, and suppressed tumor growth. Moreover, Tim-3 blockade synergized effectively with both anti-PD-1 and lenvatinib to achieve sustained tumor control. CONCLUSION: Our findings establish Tim-3 as a pivotal regulator of DC ferroptosis in metabolic liver cancer. Combining Tim-3 blockade with standard therapies represents a promising strategy to restore immune surveillance in MASLD-HCC. IMPACT AND IMPLICATIONS: Our findings identify Tim-3 as a crucial metabolic immune checkpoint that governs dendritic cell ferroptosis and dendritic cell-mediated antitumor immunity in metabolic liver cancer. Targeted blockade of Tim-3 in dendritic cells holds great therapeutic potential for the treatment of steatohepatitis-related hepatocellular carcinoma, particularly for patients with metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma who exhibit resistance to anti-PD-1 therapy.
引用
- Li N, Song X, Peng X, et al. Tim-3 facilitates dendritic cell ferroptosis and impairs antitumor immunity in steatohepatitis-related HCC. J Hepatol. 2026. PMID: 42035954. doi:10.1016/j.jhep.2026.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。